Esperion Therapeutics, Inc. (Nasdaq:ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announced that it will host a conference call and webcast on Tuesday, September 3, 2013 at 8:30 a.m. Eastern Time (ET) to present top-line results from a Phase 2a clinical study of its lead product candidate, ETC-1002, as an add-on to statin therapy in patients with hypercholesterolemia.
The live event will be accessible on the Esperion website beginning at 8:30 a.m. at www.esperion.com, under the Investors section, or by calling (877) 312-7508 (domestic) or (253) 237-1184 (international). The access code is 28976349. A replay of the event will be available beginning at approximately 10:00 a.m. ET on September 3, 2013 from the Esperion website or by calling (855) 859-2056 (domestic) or (404) 537-3406 (international), using access code 28976349. The replay will be available through September 17, 2013.
About Esperion Therapeutics
Esperion Therapeutics, Inc. is a biopharmaceutical company focused on the research, development and commercialization of therapies for the treatment of patients with elevated levels of LDL-C and other cardiometabolic risk factors. ETC-1002, Esperion's lead product candidate, is a unique, first-in-class, orally available, once-daily small molecule designed to lower levels of LDL-C and to avoid side effects associated with existing LDL-C lowering therapies. ETC-1002 is targeted for statin intolerant patients with elevated levels of LDL-C. Esperion has completed seven clinical studies to date, including four Phase 2a studies, and expects to initiate a robust Phase 2b clinical program in the fourth quarter of 2013. For more information, please visit www.esperion.com.
Forward Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the anticipated timing of Esperion’s Phase 2b clinical program. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause Esperion's actual results to differ significantly from those projected, including, without limitation, the risk that unanticipated developments could interfere with the development (and commercialization) of ETC-1002, as well as other risks detailed in Esperion's filings with the Securities and Exchange Commission, including our Quarterly Report on Form 10-Q filed with Securities and Exchange Commission on August 12, 2013. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. Esperion disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law.
|Esperion Therapeutics Announces Positive Top-Line Results from Phase 2 Clinical Study of ETC-1002 as an Add-On to Statin Therapy in Patients with Hypercholesterolemia ()|
|Chimerix Announces Top Line Data From CMX001 Phase 2 Adenovirus Study and Late-Breaker Presentation at ICAAC ()|
|Esperion Therapeutics Announces Initiation of Phase 2b Clinical Study of ETC-1002 in Patients With or Without Statin Intolerance and Hypercholesterolemia (2013/10/30)|
|Keryx Biopharmaceuticals to Hold Conference Call Tomorrow, November 5, 2013, at 8:30AM ET to Discuss Top-Line Results from Zerenex(TM) Phase 2 Study of Non-Dialysis Dependent Chronic Kidney Disease Patients with Elevated Serum Phosphorus and Iron Deficiency Anemia (2013/11/4)|
|Bard to Host Conference Call on September 4, 2013 ()|
|Endurance to Report 2013 Third Quarter Results and Host Conference Call on December 3, 2013 (2013/11/20)|
|Ocean Power Technologies to Announce Fiscal First Quarter Results and Host Conference Call on September 13, 2013 (2013/9/3)|
|Affymetrix to Host Conference Call on October 30th, 2013 to Announce Third Quarter 2013 Operating Results (2013/10/2)|
|Techne Corporation To Host Conference Call On October 29, 2013 To Announce First Quarter Financial Results (2013/10/23)|
|Esperion Therapeutics Presents Full Results of Phase 2 Clinical Study Demonstrating that ETC-1002 Lowered LDL-C by an Average of 32 Percent and Was Well Tolerated in Patients with Hypercholesterolemia and History of Statin Intolerance (2013/11/18)|
|Start Premium Trial||Register For Free|
|P||F||Fund Financial Data (13,000+ funds)|
|P||F||Stock Financial Data (7,000+ stocks)|
|P||F||Stock and Fund Screeners (basic)|
|P||F||Investing Articles and Market Commentary|
|P||F||Articles Archive (>30 days)|
|P||F||Discuss (dozens of stock, fund, bond, and general bulletin boards)|
|P||F||Portfolio Manager (basic)|
|P||F||Morningstar Investment Classroom|
|P||F||Access Your Portfolio Anytime, Anywhere via Your Mobile Device|
|P||Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)|
|P||Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)|
|P||Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)|
|P||Portfolio Monitor (monthly and on-demand personalized portfolio statements)|
|P||Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)|
|P||Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters|
|P||Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)|
|P||Discounts on Morningstar newsletters, books, seminars, and more|
Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.
Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.